Skip to main content

Immunosuppression

5
Pipeline Programs
10
Companies
10
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
4
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
4100%
+ 9 programs with unclassified modality

Competitive Landscape

10 companies ranked by most advanced pipeline stage

Chiesi
ChiesiBrazil - Santana de Parnaíba
1 program
1
Tacrolimus PillPhase 41 trial
Active Trials
NCT06268769Recruiting300Est. Sep 2029
MSD
MSDIreland - Ballydine
1 program
1
Virosomal influenza vaccinePhase 4Vaccine
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
Virosomal influenza vaccinePhase 4Vaccine1 trial
Active Trials
NCT00783380Completed304Est. Mar 2008
Abbott
AbbottABBOTT PARK, IL
1 program
1
Virosomal influenza vaccinePhase 4Vaccine
Novavax
NovavaxMD - Gaithersburg
1 program
1
NVX-CoV2372Phase 21 trial
Active Trials
NCT06027229Completed21Est. Sep 2024
Sandoz
SandozAustria - Kundl
4 programs
Arm A: EverolimusN/A1 trial
MyforticN/A1 trial
MyforticN/A1 trial
Hydroxychloroquine Sulfate Tablets, 200 mgPHASE_11 trial
Active Trials
NCT01936519Completed24Est. Jul 2019
NCT00336817Completed30Est. Nov 2008
NCT00336895Completed29Est. Nov 2008
+1 more trials
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
MicrosamplingN/A1 trial
Active Trials
NCT04989686Completed66Est. May 2025
Chong Kun Dang Pharmaceutical
1 program
Tacrobell capsule 1mgN/A1 trial
Active Trials
NCT01910077Completed50Est. Nov 2013
Astellas
AstellasChina - Shenyang
1 program
The Differential Effects of 3 Different ImmunosuppressiveN/A1 trial
Active Trials
NCT00729248Completed12Est. Jan 2010
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
Virosomal influenza vaccinePHASE_4Vaccine

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
ChiesiTacrolimus Pill
Sharp TherapeuticsVirosomal influenza vaccine
NovavaxNVX-CoV2372
SandozHydroxychloroquine Sulfate Tablets, 200 mg
Human BioSciencesMicrosampling
SandozArm A: Everolimus
Chong Kun Dang PharmaceuticalTacrobell capsule 1mg
AstellasThe Differential Effects of 3 Different Immunosuppressive
SandozMyfortic
SandozMyfortic

Clinical Trials (10)

Total enrollment: 908 patients across 10 trials

NCT06268769ChiesiTacrolimus Pill

Tacrolimus C:D Ratio Measured in Renal Transplant Recipients Treated With Once-daily Prolonged-release Drugs

Start: Mar 2024Est. completion: Sep 2029300 patients
Phase 4Recruiting
NCT00783380Sharp TherapeuticsVirosomal influenza vaccine

Influenza Vaccination in Immunocompromized Patients

Start: Oct 2005Est. completion: Mar 2008304 patients
Phase 4Completed
NCT06027229NovavaxNVX-CoV2372

Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed Populations

Start: Nov 2023Est. completion: Sep 202421 patients
Phase 2Completed
NCT00946790SandozHydroxychloroquine Sulfate Tablets, 200 mg

To Demonstrate the Relative Bioavailability of Hydroxychloroquine Sulfate, 200 mg Tablets

Start: Jul 1993Est. completion: Dec 199372 patients
Phase 1Completed
NCT04989686Human BioSciencesMicrosampling

Microsampling Assays for Immunosuppressive Drugs in Children

Start: Jun 2023Est. completion: May 202566 patients
N/ACompleted
NCT01936519SandozArm A: Everolimus

Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation.

Start: Dec 2013Est. completion: Jul 201924 patients
N/ACompleted
NCT01910077Chong Kun Dang PharmaceuticalTacrobell capsule 1mg

Bioequivalence Study of Tacrobell Capsule 1mg to Prograf Capsule 1mg

Start: Aug 2013Est. completion: Nov 201350 patients
N/ACompleted
NCT00729248AstellasThe Differential Effects of 3 Different Immunosuppressive

The Differential Effects of 3 Different Immunosuppressive

Start: Jul 2008Est. completion: Jan 201012 patients
N/ACompleted
NCT00336817SandozMyfortic

A Prospective Study on the Tolerability and Efficacy of the de Novo Use of Myfortic in Liver Transplant Recipients

Start: Nov 2006Est. completion: Nov 200830 patients
N/ACompleted
NCT00336895SandozMyfortic

Conversion of CellCept to Myfortic: A Prospective Study in Liver Transplant Recipients

Start: Nov 2006Est. completion: Nov 200829 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 908 patients
10 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.